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Abstract
A temocillin minimal inhibitory concentration  128 mg/L com-
bined with the results of meropenem double disc synergy testing
was used to (i) discriminate carbapenemase production from
other resistance mechanisms leading to decreased carbapenem
susceptibility; and (ii) differentiate Ambler classes in carbapenem-
ase-producing enterobacteriaceae (CPE). The suggested test algo-
rithm discriminated all extended spectrum ß-lactamase/AmpC
from CPE isolates, which could further be divided correctly into
Ambler classes A and B enzymes as well as OXA-48 in all cases.
The algorithm is simple to implement as part of the daily routine in
a standard microbiology laboratory with limited access to or
resources for molecular biological tools.
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Increasing numbers of carbapenemase-producing Enterobacte-
riaceae (CPE) are reported both globally [1] and from Austria
[2]. For Ambler class A and B carbapenemases expressing
isolates, well-deﬁned phenotypical detection and conﬁrmation
methods based on speciﬁc inhibitors have been described [3].
Although Ambler class D enzymes may be inhibited by NaCl
[4], no reliable speciﬁc phenotypic test for these enzymes has
been published so far. With regard to Enterobacteriaceae the
most important enzyme in this latter group is OXA-48 and its
variants. Recently published data suggest high level resistance
of OXA-48-positive isolates to temocillin [5], a semi-synthetic
betalactam antibiotic with excellent in vitro activity against most
Enterobacteriaceae species, including extended spectrum ß-
lactamase (ESBL) and AmpC producing isolates [6]. In this
study, we differentiated Ambler classes A and B and OXA-48
CPE from isolates expressing other resistance mechanisms
leading to decreased carbapenem susceptibility using a com-
mercially available meropenem-based double disc synergy test
(DDST) in combination with temocillin minimal inhibitory
concentration (MIC) determination.
Seventy-eight Enterobacteriaceae strains isolated between
August 2010 and May 2012 in all parts of Austria and referred
to the national reference laboratory due to reduced carba-
penem susceptibility were included in this study. Molecular
identiﬁcation as determined by means of the DNA microarray
Check-MDR CT102 kit (Checkpoints, Wageningen, the
Netherlands) and an AmpC multiplex PCR [7], but with an
annealing temperature of 58°C, revealed the following carb-
apenemase and ESBL genes: blaKPC (n = 15), blaNDM
(n = 5), blaOXA-48 (n = 16), blaVIM (n = 10), blaOXA-48
and blaVIM (n = 2), blaCTX-M (n = 14), blaSHV (n = 1) and
blaAmpC (n = 15).
Meropenem and temocillin MICs were determined by
means of gradient diffusion testing (Etest; bioMerieux, Marcy
l’Etoile, France) as described by the manufacturer.
Phenotypic testing for carbapenemases was performed by
means of the DDST KPC + MBL Conﬁrm ID kit (Rosco Diagnos-
tica A/S, Taastrup, Denmark) using meropenem discs alone and in
combination with dipicolinic acid, aminophenylboronic acid and
cloxacillin as recommended by the manufacturer.
The modiﬁed Hodge test using ertapenem, imipenem and
meropenem discs was carried out on all strains as described by
the Clinical and Laboratory Standards Institute [8].
Meropenem and temocillin MICs are displayed in Table 1.
Meropenem MICs of all tested isolates and OXA-48 CPE in
particular ranged from 0.016 to 32 mg/L and from 0.25 to
32 mg/L, respectively. Temocillin MICs of all tested isolates and
OXA-48 CPE in particular ranged from 4 to 1024 mg/L and
from 128 to1024 mg/L, respectively. If a temocillin cut-off value
of  128 mg/L was set, 31 of 78 strains (40%) fell into this
category and consisted of Ambler Class A (2/15), B (11/15) and
all OXA-48 (18/18) CPE. Fig. 1 displays the temocillin MIC
distribution of the tested isolates sorted by resistance mech-
anism, as determined by molecular biology. All AmpC (n = 15)
and ESBL (n = 15) isolates (temocillin MICs range, 4–64 mg/L)
fell into the category below the cut-off value. The highest MIC
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values of 64 mg/L in two such isolates were detected in one
AmpC (blaDHA) and one ESBL (blaCTX-M1) carrying strain.
TheKPC + MBLConﬁrm IDkit identiﬁed 2/2 (100%)Ambler
class A and 12/13 (92, 3%)Ambler class BCPE correctly in the 31
strains with a temocillin MIC  128 mg/L. One out of two
isolates harboring OXA-48 and VIM simultaneously was classi-
ﬁed as Ambler class B; the other one had a negative result. All
other OXA-48 CPEs revealed negative results by DDST.
The modiﬁed Hodge test revealed a positive or at least weak
positive result for at leastoneoutof the threecarbapenems applied
in 12 /18 OXA-48 strains (66, 7%; data not shown). Six OXA-48
strains, however, were negative in the modiﬁed Hodge test.
In this current era of emerging carbapenemases it is critically
important for hospital hygiene and epidemiology to discriminate
carbapenemase production from other resistance mechanisms
causing reduced susceptibility to carbapenems [9]. Without
access to molecular biology the assignment of a raised carba-
penem MIC in Enterobacteriaceae to its underlying resistance
mechanism(s) can, however, turn into a cumbersome under-
taking. Awide variety of enzymes other than carbapenemases, as
well as porin changes or a combination of both, can result in
phenotypes not distinguishable by a single phenotypic test and
new enzymes are being steadily described [10]. The question of
whether one should screen for carbapenemase production and,
if yes, which ß-lactam antibiotic should be used as a substrate
(and breakpoint), is difﬁcult to answer [11].
Based on locally isolated CPEs, national antimicrobial
susceptibility testing committee Austria currently recommends
use of meropenem (MIC  0.5 lg/L) rather than imipenem
or ertapenem [12] as a screening agent for CPE in Austria
(www.referenzzentrum.at).
Detection of OXA-48, the most important Ambler class D
enzyme, is especially challenging. The investigated OXA-48
isolates in our study had meropenem MICs ranging from wild-
TABLE 1. Resistance mechanisms and MIC (mg/L) distribu-
tions of meropenem and temocillin
Meropenem
MIC range
Temocillin
MIC range
Klebsiella pneumoniae, n = 47
Ambler A n = 15 4–32 32–512
Ambler B n = 2 8–32 16–64
Ambler D n = 7 1–32 1024
Ambler B + D n = 1 4 1024
AmpC n = 12 0.032–32 16–64
ESBL n = 10 0.032–8 8–32
Escherichia coli, n = 15
Ambler B n = 3 0.5–16 128–512
Ambler D n = 6 0.5–2 512–1024
AmpC n = 1 16 16
ESBL n = 5 0.016–4 8–64
Enterobacter cloacae, n = 5
Ambler B n = 5 2–32 32–1024
Klebsiella oxytoca n = 4
Ambler B n = 4 0.5–2 64–256
Citrobacter freundii, n = 2
Ambler B n = 1 32 1024
Ambler B + D n = 1 1 1024
Morganella morganii, n = 2
Ambler D n = 2 0.25–0.5 128–512
Enterobacter amnigenus, n = 1
AmpC n = 1 32 16
Proteus mirabilis n = 1
AmpC n = 1 4 4
Serratia marcescens, n = 1
Ambler D n = 1 32 1024
Total number n = 78
MIC, minimal inhibitory concentration.
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FIG. 1. Temocillin MIC distribution of the tested isolates sorted by resistance mechanism. MIC, minimal inhibitory concentration; CPE,
carbapenemase producing Enterobacterium; ESBL, extended spectrum ß-lactamase.
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type distribution (www.eucast.org) to up to >32 mg/L and
one-third was negative in the modiﬁed Hodge test. The only
commercial DDST did not detect OXA-48, as expected, and
there are very limited published data on other phenotypical
detection options. Therefore, the additional use of temocillin
MICs seemed to us an interesting approach in further
identifying these microorganisms, especially because AmpC
and ESBL-expressing organisms can mimic OXA-48 signiﬁ-
cantly. Our results demonstrated very good results for
temocillin MICs of  128 mg/L to have a suspicion for
OXA-48 production, though the presence of other carbape-
nemase types cannot be excluded. Compared with other
phenotypical test systems for detection of Ambler class D
carbapenemases such as the modiﬁed Hodge test [12], MIC
determination using gradient diffusion is a standardized
procedure without a subjective component. Interestingly, our
results of the modiﬁed Hodge test concerning the detection
rate of OXA-48 CPE are contrary to the data shown in the
literature [4].
When combining temocillin MICs with the commercially
available meropenem DDST we could sort out ESBLs and
AmpC from OXA-48 CPE by means of the temocilllin MIC
cut-off of  128 mg/L and assign the remaining strains to class
A and B CPE by means of the DDST. The suggested method is
easy to implement and cheap. Even though we are well aware
that the total number of isolates studied was low and the
strategy needs to be validated much more extensively, it
maybe worthwhile to follow-up the suggested approach. This
could lead to a better detection rate of CPE, especially for
OXA-48 and ‘conﬂicting isolates’ that harbour multiple
resistance mechanisms simultaneously. Laboratories with lim-
ited access to or resources for molecular biological tools,
which remain the reference standard in CPE conﬁrmation
testing [12], might ﬁnd this algorithm useful.
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